Caenorhabditis elegans bacterial pathogen resistant bus-4 mutants produce altered mucins

Lisa M Parsons1, Rahman M Mizanur1, Ewa Jankowska1

  • 1Food and Drug Administration, Center for Biologics Evaluation and Research, Bethesda, Maryland, United States of America.

Plos One
|October 9, 2014
PubMed

Insights

Caenorabditis elegans bus-4 mutants show altered glycosylation, conferring resistance to bacterial pathogens. These changes in N- and O-glycans create a barrier, preventing pathogen attachment and infection.

Area of Science:

  • Glycobiology
  • Nematology
  • Microbiology

Background:

  • Caenorhabditis elegans bus-4 glycosyltransferase mutants exhibit resistance to several bacterial pathogens.
  • Understanding the underlying glycosylation changes is crucial for elucidating pathogen resistance mechanisms.

Purpose of the Study:

  • To define the specific glycosylation alterations in bus-4 mutants.
  • To correlate these changes with observed pathogen resistance phenotypes.

Main Methods:

  • Mass spectrometry (MALDI-TOF MS, tandem MS, GC/MS) for glycan structural analysis.
  • Quantitative expression analysis of mucin genes (let-653, osm-8) and GDP-Man 4,6 dehydratase.
  • Lectin binding studies to assess cell surface glycoconjugate distribution.

Main Results:

  • Significant alterations in both O-glycan and N-glycan pools were observed in bus-4 mutants.
  • Increased abundance of Ce core-I and fucosyl O- and N-glycans.
  • Upregulation of mucins and GDP-Man 4,6 dehydratase, with altered surface glycoconjugate distribution.

Conclusions:

  • Altered mucin abundance, charge, and terminal substitutions contribute to pathogen resistance.
  • Changes in cell surface and intestinal glycoconjugates likely impede bacterial recognition and infection.
  • Glycosylation modifications in bus-4 mutants provide a defense mechanism against specific bacterial pathogens.

Related Concept Videos